FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379283452> ?p ?o ?g. }

• W4379283452 endingPage "12104" @default.
• W4379283452 startingPage "12104" @default.
• W4379283452 abstract "12104 Background: Cisplatin-induced acute kidney injury (C-AKI) is a common reason for treatment interruption in head and neck cancer patients who receive chemoradiotherapy (CRT). We developed a risk prediction model for C-AKI in patients from a randomized phase II/III trial of JCOG1008, which demonstrated that CRT with weekly cisplatin at 40 mg/m 2 (weekly arm) was noninferior to 3-weekly cisplatin at 100 mg/m 2 (3-weekly arm) in terms of overall survival for postoperative high-risk head and neck cancer ( J Clin Oncol 2022; 40: 1980-90). Methods: Two hundred fifty-one patients received RT with a total of 66 Gy/33 fr concurrently with 3-weekly or weekly cisplatin. AKI was defined using the AKI Network classification/staging system as an increase in serum creatinine of ≥0.3 mg/dL or a 1.5-fold or greater increase from baseline (≥ stage I) by 30 days after the completion of CRT. AKI risk prediction models were developed by combining explanatory variables which were expected to contribute, including age, sex, ECOG performance status, primary site, pathological stage, diabetes mellites, hypertension, main nutritional method, treatment arm, serum albumin, serum magnesium, and creatinine clearance (CCr) at registration. A logistic regression model with the Akaike information criterion was used to explore the optimal model. Results: Ninety-four of 251 (37.5%) patients developed C-AKI in this study. The optimal C-AKI risk prediction model was composed of four factors, including a primary site (hypopharynx/larynx or oral cavity/oropharynx, odds ratio [OR] 1.92 [95% CI, 1.10 to 3.30]), treatment arm (3-weekly arm or weekly arm, OR 1.75 [95% CI, 1.02 to 3.00]), serum albumin (≤ 3.5 g/dL or > 3.5 g/dL, OR 2.06 [95% CI, 1.11 to 3.87]) and CCr ( < 90 mL/min or ≥ 90 mL/min, OR 1.85 [95% CI, 1.05 to 3.26]). The incidence of C-AKI increased in accordance with a total count of the four factors (Table): with a total count of 0-1, 2 and 3-4, the incidence of clinically relevant stage II/III C-AKI was 2.9%, 11.5%, and 22.6%, respectively. When total count was ≤1, the positive and negative predictive values for stage II/III C-AKI development were 16.1% and 97.0%, respectively. Conclusions: We developed a risk prediction model for C-AKI in head and neck cancer patients who receive CRT using primary site, cisplatin administration method, serum albumin, and CCr. The high negative predictive value of this prediction model may help rule out the development of moderate to severe C-AKI. Clinical trial information: jRCTs031180135 . [Table: see text]" @default.
• W4379283452 created "2023-06-05" @default.
• W4379283452 creator A5000548560 @default.
• W4379283452 creator A5003403184 @default.
• W4379283452 creator A5011675274 @default.
• W4379283452 creator A5023855103 @default.
• W4379283452 creator A5023937165 @default.
• W4379283452 creator A5026670794 @default.
• W4379283452 creator A5034582186 @default.
• W4379283452 creator A5035762079 @default.
• W4379283452 creator A5037232399 @default.
• W4379283452 creator A5041410809 @default.
• W4379283452 creator A5043929201 @default.
• W4379283452 creator A5044638012 @default.
• W4379283452 creator A5050468802 @default.
• W4379283452 creator A5051636789 @default.
• W4379283452 creator A5060609402 @default.
• W4379283452 creator A5066036934 @default.
• W4379283452 creator A5066514747 @default.
• W4379283452 creator A5069640225 @default.
• W4379283452 creator A5071627426 @default.
• W4379283452 creator A5089037165 @default.
• W4379283452 date "2023-06-01" @default.
• W4379283452 modified "2023-09-23" @default.
• W4379283452 title "A risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer who receive chemoradiotherapy: A supplement analysis of a phase II/III trial of JCOG1008." @default.
• W4379283452 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.12104" @default.
• W4379283452 hasPublicationYear "2023" @default.
• W4379283452 type Work @default.
• W4379283452 citedByCount "0" @default.
• W4379283452 crossrefType "journal-article" @default.
• W4379283452 hasAuthorship W4379283452A5000548560 @default.
• W4379283452 hasAuthorship W4379283452A5003403184 @default.
• W4379283452 hasAuthorship W4379283452A5011675274 @default.
• W4379283452 hasAuthorship W4379283452A5023855103 @default.
• W4379283452 hasAuthorship W4379283452A5023937165 @default.
• W4379283452 hasAuthorship W4379283452A5026670794 @default.
• W4379283452 hasAuthorship W4379283452A5034582186 @default.
• W4379283452 hasAuthorship W4379283452A5035762079 @default.
• W4379283452 hasAuthorship W4379283452A5037232399 @default.
• W4379283452 hasAuthorship W4379283452A5041410809 @default.
• W4379283452 hasAuthorship W4379283452A5043929201 @default.
• W4379283452 hasAuthorship W4379283452A5044638012 @default.
• W4379283452 hasAuthorship W4379283452A5050468802 @default.
• W4379283452 hasAuthorship W4379283452A5051636789 @default.
• W4379283452 hasAuthorship W4379283452A5060609402 @default.
• W4379283452 hasAuthorship W4379283452A5066036934 @default.
• W4379283452 hasAuthorship W4379283452A5066514747 @default.
• W4379283452 hasAuthorship W4379283452A5069640225 @default.
• W4379283452 hasAuthorship W4379283452A5071627426 @default.
• W4379283452 hasAuthorship W4379283452A5089037165 @default.
• W4379283452 hasConcept C121608353 @default.
• W4379283452 hasConcept C126322002 @default.
• W4379283452 hasConcept C126894567 @default.
• W4379283452 hasConcept C141071460 @default.
• W4379283452 hasConcept C143998085 @default.
• W4379283452 hasConcept C156957248 @default.
• W4379283452 hasConcept C2776530083 @default.
• W4379283452 hasConcept C2776694085 @default.
• W4379283452 hasConcept C2776907518 @default.
• W4379283452 hasConcept C2778239845 @default.
• W4379283452 hasConcept C2778424827 @default.
• W4379283452 hasConcept C2780306776 @default.
• W4379283452 hasConcept C2780472472 @default.
• W4379283452 hasConcept C44249647 @default.
• W4379283452 hasConcept C71924100 @default.
• W4379283452 hasConceptScore W4379283452C121608353 @default.
• W4379283452 hasConceptScore W4379283452C126322002 @default.
• W4379283452 hasConceptScore W4379283452C126894567 @default.
• W4379283452 hasConceptScore W4379283452C141071460 @default.
• W4379283452 hasConceptScore W4379283452C143998085 @default.
• W4379283452 hasConceptScore W4379283452C156957248 @default.
• W4379283452 hasConceptScore W4379283452C2776530083 @default.
• W4379283452 hasConceptScore W4379283452C2776694085 @default.
• W4379283452 hasConceptScore W4379283452C2776907518 @default.
• W4379283452 hasConceptScore W4379283452C2778239845 @default.
• W4379283452 hasConceptScore W4379283452C2778424827 @default.
• W4379283452 hasConceptScore W4379283452C2780306776 @default.
• W4379283452 hasConceptScore W4379283452C2780472472 @default.
• W4379283452 hasConceptScore W4379283452C44249647 @default.
• W4379283452 hasConceptScore W4379283452C71924100 @default.
• W4379283452 hasIssue "16_suppl" @default.
• W4379283452 hasLocation W43792834521 @default.
• W4379283452 hasOpenAccess W4379283452 @default.
• W4379283452 hasPrimaryLocation W43792834521 @default.
• W4379283452 hasRelatedWork W1764476294 @default.
• W4379283452 hasRelatedWork W1964607020 @default.
• W4379283452 hasRelatedWork W2085529382 @default.
• W4379283452 hasRelatedWork W2541811369 @default.
• W4379283452 hasRelatedWork W2888911731 @default.
• W4379283452 hasRelatedWork W2931659891 @default.
• W4379283452 hasRelatedWork W2947619045 @default.
• W4379283452 hasRelatedWork W3037956623 @default.
• W4379283452 hasRelatedWork W3176367524 @default.
• W4379283452 hasRelatedWork W4308006065 @default.
• W4379283452 hasVolume "41" @default.
• W4379283452 isParatext "false" @default.
• W4379283452 isRetracted "false" @default.
• W4379283452 workType "article" @default.